0001367644false00013676442024-10-022024-10-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): October 2, 2024
 
EMERGENT BIOSOLUTIONS INC.
(Exact name of registrant as specified in its charter)
 
Delaware001-3313714-1902018
(State or other jurisdiction(Commission File Number)(IRS Employer
of incorporation)Identification No.)
  300 Professional Drive,
Gaithersburg, Maryland 20879
(Address of principal executive offices, including zip code)
 
(240) 631-3200
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareEBSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company     ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)     On October 2, 2024, the Compensation Committee of the Board of Directors of Emergent BioSolutions Inc. (the “Company”), approved a special one-time discretionary equity award to be granted to Richard S. Lindahl, the Company’s Executive Vice President, Chief Financial Officer and Treasurer of 15,000 restricted stock units, which will have a grant date of October 15, 2024 and will vest on the first anniversary of the date of grant (the “Award”). The Award is subject to Mr. Lindahl's continued employment with the Company through the applicable vesting date, the terms and conditions of the Company’s Amended and Restated Stock Incentive Plan, Global Restricted Stock Unit Award Agreement, and Second Amended and Restated Senior Management Severance Plan. This Award is in recognition of Mr. Lindahl’s substantial contributions in executing recent strategic initiatives.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EMERGENT BIOSOLUTIONS INC.
   
Dated: October 4, 2024By:/s/ Jessica Perl
Name: Jessica Perl
Title: VP, Corporate Secretary and
Interim General Counsel

v3.24.3
Cover Page Cover Page
Oct. 02, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Oct. 02, 2024
Entity Registrant Name EMERGENT BIOSOLUTIONS INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-33137
Entity Tax Identification Number 14-1902018
Entity Address, Address Line One 300 Professional Drive
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20879
City Area Code 240
Local Phone Number 631-3200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol EBS
Security Exchange Name NYSE
Entity Central Index Key 0001367644
Amendment Flag false
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Emergent Biosolutions Charts.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Emergent Biosolutions Charts.